Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03630211 · ClinicalTrials.gov registry record · Phase 2
Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
A Phase 2 study of Pulmonary Hypertension and Interstitial Lung Disease, sponsored by Paul Szabolcs.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
- 3
- Study locations
NCT03630211 is a Phase 2 study of Pulmonary Hypertension and Interstitial Lung Disease that is actively recruiting participants, run by Paul Szabolcs. The registered enrollment target is 8 participants, below the 614-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT03630211, a Phase 2 study of Pulmonary Hypertension and Interstitial Lung Disease, is actively recruiting participants, sponsored by Paul Szabolcs.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to determine whether a regimen of high-dose immunoablative therapy will demonstrate safety that is consistent or improved with other published regimens in SSc patients, while maintaining a treatment effect.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Alemtuzumab
- DRUG Mesna
- DRUG Rituximab
- DRUG Thiotepa
Study Locations (3)
Pennsylvania
- Children's Hospital of Pittsburgh of UPMC - Pittsburgh
- University of Pittsburgh Medical Center - Pittsburgh
- University of Pittsburgh Medical Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2018-07-31 |
| Est. Completion | 2026-08-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03630211
The ClinicalTrials.gov registry entry for NCT03630211 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 614-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (99% lower). The listed sponsor is Paul Szabolcs, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Pulmonary Hypertension appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT03630211 reports 3 study locations spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03630211 about?
NCT03630211 is a clinical study titled "Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis". The purpose of this study is to determine whether a regimen of high-dose immunoablative therapy will demonstrate safety that is consistent or improved with other published regimens in SSc patients, while maintaining a treatment effect.
What is the current status of trial NCT03630211?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2018-07-31. Estimated completion is 2026-08-01.
What conditions does trial NCT03630211 study?
This clinical trial studies the following conditions: Pulmonary Hypertension, Interstitial Lung Disease, Systemic Sclerosis, Diffuse Sclerosis Systemic.
What interventions are being tested in trial NCT03630211?
The interventions under investigation include: Cyclophosphamide (DRUG), Alemtuzumab (DRUG), Mesna (DRUG), Rituximab (DRUG), Thiotepa (DRUG).
Who is sponsoring clinical trial NCT03630211?
This trial is sponsored by Paul Szabolcs, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03630211 being conducted?
This trial has 3 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Trial of Phosphodiesterase-5 Inhibitor in Neonatal Congenital Diaphragmatic Hernia (TOP-CDH)
RECRUITING · Phase 2
-
Xenon MRI Pulm Hypertension
RECRUITING · Phase 2
-
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
RECRUITING · Phase 2
-
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
RECRUITING · Phase 2
-
Metformin for Pulmonary Hypertension HFpEF
RECRUITING · Phase 2
-
A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.